-+ 0.00%
-+ 0.00%
-+ 0.00%

Peptron Wins South Korean Approval for PT403 Phase 1 Obesity Trial

PUBT·11/18/2026 22:50:00
Listen to the news
Peptron Wins South Korean Approval for PT403 Phase 1 Obesity Trial
  • Peptron received South Korean regulatory clearance on Nov. 18, 2026, for a Phase 1 trial of obesity candidate PT403.
  • The trial will assess safety, tolerability and pharmacokinetics in 22 healthy adults, with completion expected Nov. 30, 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Peptron Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261119900001), on November 19, 2026, and is solely responsible for the information contained therein.